Citius Pharmaceuticals, Inc. (NASDAQ:CTXR – Get Free Report) shares crossed below its 50-day moving average during trading on Monday. The stock has a 50-day moving average of $0.53 and traded as low as $0.51. Citius Pharmaceuticals shares last traded at $0.5263, with a volume of 265,436 shares.
Wall Street Analyst Weigh In
A number of equities analysts have recently issued reports on the stock. HC Wainwright reissued a “buy” rating on shares of Citius Pharmaceuticals in a research report on Wednesday, August 19th. Citigroup restated a “buy” rating on shares of Citius Pharmaceuticals in a research note on Wednesday, August 19th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Citius Pharmaceuticals in a report on Monday, September 21st. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Citius Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $6.00.
Get Our Latest Stock Report on CTXR
Citius Pharmaceuticals Price Performance
The stock has a market cap of $14.45 million, a price-to-earnings ratio of -0.32 and a beta of 1.05. The company has a debt-to-equity ratio of 0.08, a quick ratio of 0.40 and a current ratio of 0.84. The company has a 50-day simple moving average of $0.53 and a two-hundred day simple moving average of $0.65.
Citius Pharmaceuticals (NASDAQ:CTXR – Get Free Report) last issued its earnings results on Friday, August 14th. The company reported ($0.34) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.02. As a group, equities research analysts forecast that Citius Pharmaceuticals, Inc. will post -2.03 EPS for the current year.
Hedge Funds Weigh In On Citius Pharmaceuticals
An institutional investor recently bought a new position in Citius Pharmaceuticals stock. BlackRock Inc. acquired a new stake in Citius Pharmaceuticals, Inc. (NASDAQ:CTXR – Free Report) during the second quarter, according to its most recent 13F filing with the SEC. The fund acquired 69,850 shares of the company’s stock, valued at approximately $42,000. BlackRock Inc. owned 0.25% of Citius Pharmaceuticals as of its most recent filing with the SEC. 16.88% of the stock is owned by institutional investors.
About Citius Pharmaceuticals
Citius Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for critical care, oncology and other areas with significant unmet medical needs. The company is headquartered in Cranford, New Jersey, and has primarily focused its development and commercialization activities on the U.S. healthcare market.
Citius’ lead product candidate has been Mino-Lok, an antibiotic lock solution designed to help salvage infected central venous catheters by treating catheter-related bloodstream infections while allowing the catheter to remain in place.
See Also
- Five stocks we like better than Citius Pharmaceuticals
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for Citius Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Citius Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
